CXCR5 and systemic lupus erythematosus: In contrast, the CXCR5- CD11c+ atypical B cell subsets were increase in SLE patients in comparison with HS: DN2 (27.7% vs 11.7%, p = 0.0013), aNAV (1.4% vs 0.7%, p = 0.0383), CXCR5- CD11c+ SWM (6.5% vs 2.5%, p = 0.0014) and CXCR5- CD11c+ USM (4.5% vs 2.1%, p = 0.0069) (Figures 2I–L).